New Cancer Drugs: Uncertainties & FDA Labeling Issues
Table of Contents
Published August 21, 2025
The Accelerated Approval Pathway and Lingering Questions
A importent 80% of new cancer drugs now reach the U.S. market through the Food and Drug Governance’s (FDA) accelerated approval pathway. While this expedited process offers hope to patients, it also introduces a degree of uncertainty. A recent study published in Health affairs raises critical questions about how much of this uncertainty is communicated to physicians prescribing these drugs.
What the study Found
Researchers from the London School of Economics and political Science (LSE) meticulously examined the review process for 52 cancer drugs approved by the FDA between 2019 and 2022. Their analysis revealed that the FDA drug label – the primary means of communicating data to physicians - omitted 26% of all identified uncertainties. Alarmingly, 48% of these omitted uncertainties were deemed important factors in the drug’s initial approval.
This lack of complete information raises concerns about whether doctors have a full understanding of a drug’s potential benefits and risks when prescribing it to patients, especially in the period immediately following approval when real-world data is still limited.
Why This Matters: Understanding “Uncertainties”
Uncertainties in the drug approval process aren’t necessarily negative. they represent areas where the evidence isn’t conclusive, often due to the inherent limitations of clinical trials. These limitations can include the size and diversity of the study population, the length of the trial, and the challenges of replicating real-world conditions. It’s well-established that clinical trial participants often differ from the broader patient population - typically being younger and healthier – and the FDA has acknowledged the ongoing need to improve diversity in clinical trials.
These uncertainties can relate to various factors, including data analysis, missing data, and even the selection of which results are reported. Crucially, they can also involve questions about whether a drug’s effectiveness observed in a clinical trial will translate to a broader, more diverse patient population, or the relationship between surrogate endpoints (indicators used in trials) and actual, meaningful patient outcomes.
Communication Breakdown?
The study suggests the FDA may be relying on outdated communication methods. Researchers point to the potential benefits of a “drug facts box” – a concise, structured summary of benefits and risks – as a more effective way to convey complex information to physicians. This approach has been shown to be more effective in communicating health information to the general public.
As one researcher noted, the current system doesn’t seem to adequately communicate the known evidence and limitations of drugs, especially those approved through expedited pathways. The chance exists to more clearly discuss these uncertainties within the existing section on clinical studies included on drug labels.
The issue of transparency is further complicated by ongoing efforts to improve diversity in clinical trials. As of August 21, 2025, the FDA has not yet finalized guidance on a draft policy requiring drug companies to submit Diversity